verified SJR 1,255 · Q1 • database Scopus / SJR & Web of Science indexed

United Kingdom · Taylor and Francis Ltd.

workspace_premium Q1 — Drug Discovery lock Subscription

Expert Opinion on Therapeutic Targets

Expert Opinion on Therapeutic Targets is a journal indexed in SJR in Drug Discovery and Pharmacology with an H index of 113. It has a price of 4000 €. It has an SJR impact factor of 1,255 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,255.

Expert Opinion on Therapeutic Targets focuses its scope in these topics and keywords: therapeutic, target, potential, histone, receptor, cancerepigenetic, receptorbased, proteoglycan, myelodysplastic, neurological, ...

ISSN: 1472-8222

Publisher: Taylor and Francis Ltd.

Category: Drug Discovery

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,255 Q1

H-index 113

Acceptance rate pie_chart

25% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

4.000 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,255

H-index

113

Docs (year)

Docs 3y

269

Total refs

9632

Cites 3y

1115

Citable 3y

238

Cites/Doc 2y

3.96

Ref/Doc

105.85

Immediate OA

4000 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Emerging strategies to target the dysfunctional cohesin complex in cancer

Why is the Plasmodium falciparum hexose transporter a promising new drug target?

Gut flora may offer new therapeutic targets for the traditional Chinese medicine enteric dialysis

GRK2 and GRK5 as therapeutic targets and their role in maladaptive and pathological cardiac hypertrophy

Gastrointestinal pain in functional bowel disorders: sensory neurons as novel drug targets

G-Protein-Coupled Receptors: New Approaches to Maximise the Impact of GPCRs in Drug Discovery

Functional genetic evaluation of DNA house-cleaning enzymes in the malaria parasite: dUTPase and Ap4AH are essential in Plasmodium berghei but ITPase and NDH are dispensable

Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer

Epigenetic transitions: towards therapeutic targets

Epigenetic targets in cancer and aging: dietary and therapeutic interventions

Endotoxin antagonism: conceptual basis and therapeutic potential

Emerging therapeutic strategies for transplantation-induced acute kidney injury: protecting the organelles and the vascular bed

SHOW MORE ARTICLES

Emerging targets for antimalarial drugs

5th Annual International Conference on HDL Cholesterol: Metabolic Pathways and Drug Developments

Emerging molecular targets in the treatment of bacterial meningitis

E2F1 as a molecular drug target in ovarian cancer

Drug Discovery and Development for Inflammatory Diseases

Dendritic cells: immunological features and utilisation for tumour immunotherapy

Death associated protein kinase as a potential therapeutic target

Considering Fas ligand as a target for therapy

Brain-derived neurotrophic factor as a drug target for CNS disorders

BCR-ABL as a target for novel therapeutic interventions

Association between plasma leptin and adiponectin levels and diastolic function in the general population

An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients

FAQs

Expert Opinion on Therapeutic Targets has an SJR of 1,255 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 4000 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Expert Opinion on Therapeutic Targets is 25%.

Expert Opinion on Therapeutic Targets

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Expert Opinion on Therapeutic Targets?

What is the APC / publication cost?

What is the acceptance rate?